| Detection and monitoring of metastases using PET/CT imaging using the 18F-DCFPyL (PyL) tracer, in patients starting enzalutamide to treat castration-resistant prostate cancer with small number of metastases, an equivocal result or no metastases on conventional imaging (PROSTEP-002). |
This is a study for patients with castration-resistant prostate cancer with a small number of metastases. The study focuses on the diagnostic performance for the visualization of metastases in the context of castration-resistant prostate cancer. It will allow us to know whether the experimental product (also called “product under study”) 18F-DCFPyL (PyL) is effective in detecting metastases that conventional imaging would not have detected. In addition, we are seeking to know if Positron Emission Tomography (PET) with the PyL tracer could make it possible, through its sensitivity and effectiveness, to determine the progression of prostate cancer with the appearance of new metastases having not not been visualized using standard imaging methods, such as bone scintigraphy or TACO (computed tomography). This would allow patients to initiate treatment targeting this condition earlier in the course of the disease. We also seek to demonstrate that certain metastases could be resistant to systemic therapies while others could be sensitive to them in the same patient.
Stade de la Maladie: Avancé ou métastatique
Organe: Prostate
Maladie: Cancer de la prostate mCRPC
